Bristol-Myers Squibb Company

NYSE:BMY

Drug Manufacturers - General

Healthcare
$59.56 -2.57%

-$1.42 today

Market cap
$121.75B
Beta
0.24
P/E (TTM)
15.1
EPS (TTM)
$3.56
Dividend yield
4.64%
52W Low $42.52High $62.89

Volume 9.54M

Average 11.50M

BMY Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Bristol-Myers Squibb CompanyNYSE: BMY

Net Debt · Q2 FY2026 · quarter ended Jun 2026

Net debt falls 10.3% from a year ago

Net debt stood at $34.4B at the end of Q2 FY2026, down 10.3% from a year earlier and down 6.7% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.

Context

  • Net debt amounted to 39.3% of total assets at the end of Q2 FY2026, down 1.2 pp from a year earlier.
  • Net debt increased in 1 of the last 3 fiscal years.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -10.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$34.4B-6.7% QoQ
Last fiscal yearDec 2025
$36.93B-9.6% YoY
Year agoJun 2025
$38.33B-10.3% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.3%——
1 year-9.6%——
3-year CAGR+5.3%——
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
36.93B USD
Year-over-year change
-9.6%
4-year CAGR
+4.0%

Net Debt vs competitors

How BMY compares with its peers on the latest reported figures

  • Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -10.3% is the 10th highest of 11, against a peer median of +5.2%.
  • Net debt amounts to 39.3% of total assets for BMY, versus a peer median of 33.1%.
BMY Competitors
Net Debt for BMY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABBVAbbVie Inc.Jun 2026$64.25B USD+0.4%+5.1%47.5%
PFEPfizer Inc.Jun 2026$62.22B USD+3.4%+24.4%30.9%
MRKMerck & Co., Inc.Jun 2026$47.06B USD+71.8%+23.1%36.3%
LLYEli Lilly and CompanyJun 2026$46.02B USD+26.0%+35.6%32.3%
AMGNAmgen Inc.Jun 2026$43.32B USD-10.1%+13.2%45.3%
NVSNovartis AGJun 2026$41.4B USD+59.3%+7.9%33.9%
BMYBristol-Myers Squibb CompanyJun 2026$34.4B USD-10.3%+5.3%39.3%
JNJJohnson & JohnsonSep 2026$27.74B USD+0.6%+1.8%14.1%
AZNAstraZeneca PLCSep 2026$26.21B USD+6.9%+1.5%21.9%
GILDGilead Sciences, Inc.Jun 2026$23.07B USD+16.5%-4.3%46.7%
GSKGSK plcJun 2026£15.04B GBP-20.2%-6.1%24.5%
Peer median (excluding BMY) —+5.2%+6.5%33.1%

Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents13.98B9.12B11.46B10.35B10.21B
Short-term Investments3.24B130M816M513M464M
Net Receivables12.52B13.94B15.26B14.42B14.53B
Inventory2.1B2.34B2.66B2.56B2.69B
Other Current Assets1.43B1.74B1.56B1.94B1.5B
Total Current Assets33.26B27.27B31.77B29.78B29.39B
Property, Plant & Equipment (Net)6.97B7.48B8.04B8.36B9.13B
Goodwill20.5B21.15B21.17B21.72B21.75B
Intangible Assets42.78B36.36B27.49B23.64B19.1B
Long-term Investments2.71B2.19B2.5B2.51B2.51B
Tax Assets1.44B1.34B2.77B4.24B5.38B
Other Non-current Assets1.66B1.04B1.43B2.36B2.78B
Total Non-current Assets76.05B69.55B63.39B62.82B60.65B
Total Assets109.31B96.82B95.16B92.6B90.04B
Account Payables2.95B3.04B3.26B3.6B3.58B
Short-term Debt4.95B4.26B3.12B2.05B2.26B
Tax Payables754M942M1.37B1.51B979M
Deferred Revenue00000
Other Current Liabilities11.48B11.99B12.79B14.6B14.63B
Total Current Liabilities21.87B21.89B22.26B23.77B23.42B
Long-term Debt39.61B35.06B36.65B47.6B42.85B
Deferred Tax Liabilities4.5B2.17B338M369M222M
Deferred Revenue (Non-current)326M283M300M230M169M
Other Non-current Liabilities6.13B5.05B4.59B2.87B3.05B
Total Non-current Liabilities51.44B43.81B43.41B52.44B48.12B
Total Liabilities73.31B65.7B65.67B76.22B71.53B
Common Stock292M292M292M292M292M
Retained Earnings23.82B25.5B28.77B14.91B16.9B
Accumulated OCI(1.27B)(1.28B)(1.55B)(1.24B)(1.52B)
Other Stockholders Equity00000
Minority Interest60M57M55M53M33M
Total Equity36.01B31.12B29.49B16.39B18.51B
Total Debt45.6B40.72B41.46B51.2B47.14B
Net Debt31.62B31.59B30B40.85B36.93B

Bristol-Myers Squibb Company

NYSE:BMY

Intrinsic Alpha fair value

Locked

Current Price

$59.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.